0001816233-22-000041.txt : 20220810 0001816233-22-000041.hdr.sgml : 20220810 20220810070354 ACCESSION NUMBER: 0001816233-22-000041 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220810 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220810 DATE AS OF CHANGE: 20220810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sharecare, Inc. CENTRAL INDEX KEY: 0001816233 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] IRS NUMBER: 851365053 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39535 FILM NUMBER: 221150371 BUSINESS ADDRESS: STREET 1: 255 EAST PACES FERRY ROAD NE STREET 2: SUITE 700 CITY: ATLANTA STATE: GA ZIP: 30305 BUSINESS PHONE: (404) 671-4000 MAIL ADDRESS: STREET 1: 255 EAST PACES FERRY ROAD NE STREET 2: SUITE 700 CITY: ATLANTA STATE: GA ZIP: 30305 FORMER COMPANY: FORMER CONFORMED NAME: Falcon Capital Acquisition Corp. DATE OF NAME CHANGE: 20200626 FORMER COMPANY: FORMER CONFORMED NAME: Falcon Capital Corp I DATE OF NAME CHANGE: 20200625 8-K 1 shcr-20220810.htm 8-K shcr-20220810
0001816233false00018162332022-08-102022-08-100001816233us-gaap:CommonClassAMember2022-08-102022-08-100001816233shcr:RedeemableWarrantsMember2022-08-102022-08-10


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 10, 2022
SHARECARE, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-39535
85-1365053
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
255 East Paces Ferry Road NE, Suite 700
Atlanta, Georgia 30305
(Address of principal executive offices)
Registrant's telephone number, including area code: (404) 671-4000
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange
on which registered
Common Stock, par value $0.0001 per share
SHCRThe Nasdaq Stock Market LLC
Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $11.50 per shareSHCRWThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.





Item 2.02. Results of Operations and Financial Condition.

On August 10, 2022, Sharecare, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2022. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

The information in this Item 2.02, including the press release attached as Exhibit 99.1 hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)    Exhibits.
Exhibit
Description
104
Cover Page Interactive Data File (formatted as inline XBRL and included as Exhibit 101)


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


SHARECARE, INC.


Dated: August 10, 2022
By: /s/ Justin Ferrero
Name: Justin Ferrero
Title: Chief Financial Officer



EX-99.1 2 sharecareexhibit99163022.htm EX-99.1 Document


image.jpg


Sharecare announces second quarter 2022 financial results and operational highlights

ATLANTA – August 10, 2022 – Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced financial results for the quarter ended June 30, 2022. In addition, the company announced that it has signed a memorandum of understanding for a multi-year strategic partnership with Carelon to integrate Sharecare’s advocacy capabilities into Carelon’s Health Guide services that currently support hundreds of thousands of members. Sharecare has also initiated a strategic review of its non-enterprise businesses to enhance shareholder value, which management and the board of directors do not believe is currently reflected in the share price. The company’s $50 million share repurchase program previously announced on May 12, 2022, remains in place.

“Sharecare delivered solid second quarter results exceeding revenue and EBITDA guidance with continued progress on deploying our digital first strategy to drive enhanced engagement, increased access, and improved outcomes for our clients,” said Jeff Arnold, chairman and CEO of Sharecare. “We remain confident in our ability to execute on our strategy given the continued demand and momentum in new business opportunities and client wins along with retaining our current customer base, which will support accelerated revenue growth and operating performance in 2023.”

Mr. Arnold added, “Sharecare provides a comprehensive digital health navigation platform supporting a significant number of top payors and employers to deliver value to more than 11 million members every day. We are committed to continuing to improve operating performance while advancing innovative solutions for our customers. One example of the value Sharecare continues to bring to its customers is the successful launch of Sharecare+, a digital first advocacy platform developed in partnership with Elevance Health. Our partnership with Carelon will be the next step in driving significant scale of our solution.”

Second Quarter 2022 Financial Results
All comparisons, unless otherwise noted, are to the three months ended June 30, 2021.
Revenue of $103.8 million compared to $98.5 million, an increase of $5.3 million, or 5%.
Net loss attributable to Sharecare of $29.0 million compared to net loss attributable to Sharecare of $20.2 million, an increase of $8.8 million. Adjusted net loss attributable to Sharecare of $6.8 million compared to adjusted net loss attributable to Sharecare of $3.6 million in the prior year period.
Adjusted EBITDA of $2.1 million compared to $6.6 million, a decrease of $4.5 million, which reflects increased investments in people, most importantly, as well as sales force expansion to support growth, a sunset of the high-margin health security product, and the additional costs of being a public company.
Net loss per share of $0.08 compared to $0.09, a decrease to net loss per share of $0.01, which reflects the aforementioned items impacting net loss.
Adjusted loss per share of $0.02 for both periods, which excludes the impact of non-cash and non-operational amounts.

There is no definitive timeline for the company's strategic review, nor has the board of directors made any decisions related to any actions or potential strategic alternatives to fully unlock



value of the company’s assets and potential that are not fully reflected in the market today; therefore, the company does not intend to comment further until it determines that additional disclosure is appropriate or necessary.

Financial Outlook
In light of a delayed start date for a large enterprise client, the initiation of the strategic review, changing macro-economic environment affecting life sciences, and certain cost initiatives being undertaken by the company, Sharecare is suspending financial guidance for 2022. The company will hold an analyst day in Q4 2022.

Conference Call
The company will host a conference call to review the second quarter results today, Wednesday August 10, 2022, at 8:00 a.m. EDT. The conference call can be accessed by dialing (833) 636-1352 for U.S. participants, or (412) 902-4148 for international participants, and referencing the Sharecare call; or via live audio webcast, also available online at https://investors.sharecare.com. A webcast replay of the call will be available for on-demand listening at the same link and will remain available for approximately 90 days.

Non-GAAP Financial Measures
In addition to our financial results determined in accordance with U.S. GAAP, we believe the non-GAAP measures adjusted EBITDA, adjusted net income (loss), and adjusted earnings (loss) per share (“adjusted EPS”) are useful in evaluating our operating performance. We use adjusted EBITDA, adjusted net income (loss), and adjusted EPS to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that these non-GAAP financial measures, when taken together with the corresponding GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. In particular, we believe that the use of these non-GAAP measures is helpful to our investors as these metrics are used by management in assessing the health of our business and our operating performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures.

The calculations and reconciliations of historic adjusted EBITDA, adjusted net income (loss), and adjusted EPS to net income (loss), the most directly comparable financial measure stated in accordance with GAAP, are provided below and in the accompanying financial tables. Investors are encouraged to review the reconciliations and not to rely on any single financial measure to evaluate our business.

We have not reconciled adjusted EBITDA guidance to net income (loss) because we do not provide guidance for net income (loss) or for items that we do not consider indicative of our ongoing performance, including, but not limited to, the impact of significant non-recurring items, as certain of these items are out of our control and/or cannot be reasonably predicted. Accordingly, reconciliations of adjusted EBITDA guidance to the corresponding U.S. GAAP measures are not available without unreasonable effort.

Adjusted EBITDA
We calculate adjusted EBITDA as net income (loss) adjusted to exclude (i) depreciation and amortization, (ii) interest income, (iii) interest expense, (iv) income tax (benefit) expense, (v) other (income)/expense (non-operating), (vi) share-based compensation, (vii) severance,



(viii) warrants issued with revenue contracts, (ix) net costs associated with exiting contracts, and (x) transaction and closing costs. We do not view the items excluded as representative of our ongoing operations.

Adjusted Net Income (Loss)
We calculate adjusted net income (loss) as net income (loss) attributable to Sharecare, Inc. adjusted to exclude (i) amortization of acquired intangibles, (ii) amortization of deferred financing fees, (iii) change in fair value of warrant liability and contingent consideration, (iv) share-based compensation, (v) severance, (vi) warrants issued with revenue contracts, (vii) net costs associated with exiting contracts, (viii) transaction and closing costs, and (ix) the related income tax adjustments. We do not view the items excluded as representative of our ongoing operations.

Adjusted Earnings (Loss) Per Share
We calculate adjusted EPS as adjusted net income (loss), as defined above, divided by the number of weighted average common shares outstanding - basic and diluted.

About Sharecare
Sharecare is the leading digital health company that helps people – no matter where they are in their health journey – unify and manage all their health in one place. Our comprehensive and data-driven virtual health platform is designed to help people, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. Driven by our philosophy that we are all together better, at Sharecare, we are committed to supporting each individual through the lens of their personal health and making high-quality care more accessible and affordable for everyone. To learn more, visit www.sharecare.com.

Important Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “outlook,” “target,” “reflect,” “on track,” “foresees,” “future,” “may,” “deliver,” “will,” “shall,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms, other comparable terminology (although not all forward-looking statements contain these words), or by discussions of strategy, plans, or intentions. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain.

Forward-looking statements in this press release include, but are not limited to, statements regarding a potential strategic review, our ability to realize the expected benefits of partnerships or other relationships with third parties or customers on our future growth objectives, our use of the share repurchase program and the statements under the caption “Financial Outlook.”

We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results. Descriptions of some of the factors that could cause actual results to differ materially from



these forward-looking statements are discussed in more detail in our filings with the U.S. Securities and Exchange Commission (the “SEC“), including the Risk Factors section of the Company's Annual Report of Form 10-K filed with the SEC on March 31, 2022. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Media Relations:
Jen Martin Hall
jen@sharecare.com

Investor Relations:
Evan Smith, CFA
evan.smith@sharecare.com





































SHARECARE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except share and per share amounts)

Three Months Ended
June 30,
Six Months Ended
June 30,
2022202120222021
Revenue$103,823 $98,459 $204,533 $188,661 
Costs and operating expenses:
Costs of revenue (exclusive of depreciation and amortization below)53,238 48,634 104,730 93,028 
Sales and marketing14,155 12,046 28,666 23,556 
Product and technology17,680 15,812 37,101 36,266 
General and administrative43,491 19,197 99,489 38,752 
Depreciation and amortization10,901 7,167 20,778 13,850 
Total costs and operating expenses139,465 102,856 290,764 205,452 
Loss from operations(35,642)(4,397)(86,231)(16,791)
Other income (expense):
Interest income102 21 131 29 
Interest expense(539)(7,095)(1,031)(14,105)
Other income (expense)6,827 (8,851)19,672 (20,730)
Total other income (expense)6,390 (15,925)18,772 (34,806)
Loss before income tax benefit (expense)(29,252)(20,322)(67,459)(51,597)
Income tax benefit (expense)(269)98 (361)14 
Net loss(29,521)(20,224)(67,820)(51,583)
Net (loss) income attributable to noncontrolling interest in subsidiaries(496)24 (594)(82)
Net loss attributable to Sharecare, Inc.$(29,025)$(20,248)$(67,226)$(51,501)
Net loss per share attributable to common stockholders, basic and diluted (1)
$(0.08)$(0.09)$(0.19)$(0.23)
Weighted-average common shares outstanding, basic and diluted (1)
347,334,401 228,721,591 346,122,333 225,493,435 
(1) Retroactively restated for the Reverse Recapitalization as a result of the Business Combination as described in Notes 1 and 2 of the 10-Q



SHARECARE, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share and per share amounts)

As of June 30,
2022
As of December 31,
2021
Assets
Current assets:
Cash and cash equivalents$211,574 $271,105 
Accounts receivable, net (net of allowance for doubtful accounts of $7,812 and $6,212, respectively)98,717 103,256 
Other receivables2,810 5,327 
Prepaid expenses12,330 8,819 
Other current assets2,472 2,459 
Total current assets327,903 390,966 
Property and equipment, net4,924 4,534 
Other long-term assets20,433 12,173 
Intangible assets, net156,509 155,086 
Goodwill191,294 192,442 
Total assets$701,063 $755,201 
Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity
Current liabilities:
Accounts payable$21,203 $27,155 
Accrued expenses and other current liabilities41,054 51,653 
Deferred revenue11,209 11,655 
Contract liabilities, current2,518 4,597 
Debt, current774 — 
Total current liabilities76,758 95,060 
Contract liabilities, noncurrent768 1,745 
Warrant liabilities3,330 10,820 
Long-term debt— 419 
Other long-term liabilities9,353 24,116 
Total liabilities90,209 132,160 
Commitments and contingencies
Series A convertible redeemable preferred shares, $0.0001 par value; 5,000,000 shares authorized; 5,000,000 shares issued and outstanding, aggregate liquidation preference of $50,000 as of June 30, 2022 and December 31, 202158,205 58,205 
Stockholders’ equity:
Common stock, $0.0001 par value; 600,000,000 and 600,000,000 shares authorized; 351,926,366 and 345,788,707 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively35 35 
Additional paid-in capital1,098,772 1,042,164 
Accumulated other comprehensive loss(3,170)(2,061)
Accumulated deficit(544,339)(477,113)
Total Sharecare stockholders’ equity551,298 563,025 
Noncontrolling interest in subsidiaries1,351 1,811 
Total stockholders’ equity552,649 564,836 
Total liabilities, redeemable convertible preferred stock and stockholders’ equity$701,063 $755,201 




SHARECARE, INC.
RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA
(Unaudited)
(In thousands)

Three Months Ended
June 30,
Six Months Ended
June 30,
2022202120222021
Net loss$(29,521)$(20,224)$(67,820)$(51,583)
Add:
Depreciation and amortization10,901 7,167 20,778 13,850 
Interest income(102)(21)(131)(29)
Interest expense539 7,095 1,031 14,105 
Income tax (benefit) expense269 (98)361 (14)
Other (income) expense(6,827)8,851 (19,672)20,730 
Share-based compensation18,177 2,360 51,287 14,386 
Severance411 200 770 265 
Warrants issued with revenue contracts(a)
14 (1)34 38 
Net costs associated with exiting contracts(b)
1,249 — 2,923 — 
Transaction and closing costs(c)(d)
7,025 1,319 14,397 2,022 
Adjusted EBITDA(e)
$2,135 $6,648 $3,958 $13,770 
 
 
(a)Represents the non-cash value of warrants issued to clients for meeting specific revenue thresholds.
(b)For the six months ended June 30, 2022, previously undisclosed first quarter net costs were included for comparability purposes and to display trends associated with exiting contracts during the period.
(c)For the three months ended June 30, 2022, represents costs related to the Business Combination, transaction and post-closing costs related to acquisitions, and other non-operating, non-recurring costs including $2.7 million of other non-operating, non-recurring costs, $3.1 million of reorganizational costs, and $1.2 million of acquisition-related expense.
(d)For the six months ended June 30, 2022, represents costs related to the Business Combination, transaction and post-closing costs related to acquisitions, and other non-operating, non-recurring costs including $5.9 million of other non-operating, non-recurring costs, $5.3 million of reorganizational costs, and $3.2 million of acquisition-related expense.
(e)Includes non-cash amortization associated with contract liabilities recorded in connection with acquired businesses.



SHARECARE, INC.
RECONCILIATION OF GAAP NET LOSS ATTRIBUTABLE TO SHARECARE TO ADJUSTED NET LOSS AND ADJUSTED LOSS PER SHARE
(Unaudited)
(In thousands, except share and per share amounts)

 
Three Months Ended
June 30,
Six Months Ended
June 30,
2022202120222021
Net loss attributable to Sharecare, Inc.$(29,025)$(20,248)$(67,226)$(51,501)
Add:
Amortization of acquired intangibles(a)
1,631 1,160 3,263 2,228 
Amortization of deferred financing fees70 1,656 138 3,331 
Change in fair value of warrant liability and contingent consideration(6,374)9,908 (18,742)21,656 
Share-based compensation18,177 2,360 51,287 14,386 
Severance411 200 770 265 
Warrants issued with revenue contracts(b)
14 (1)34 38 
Net costs associated with exiting contracts(c)
1,249 — 2,923 — 
Transaction and closing costs(d)(e)
7,025 1,319 14,397 2,022 
Adjusted net loss(f)
$(6,822)$(3,646)$(13,156)$(7,575)
Weighted-average common shares outstanding, basic and diluted347,334,401 228,721,591 346,122,333 225,493,435 
Loss per share$(0.08)$(0.09)$(0.19)$(0.23)
Adjusted loss per share$(0.02)$(0.02)$(0.04)$(0.03)
 
(a)Represents non-cash expenses related to the amortization of intangibles in connection with acquired businesses.
(b)Represents the non-cash value of warrants issued to clients for meeting specific revenue thresholds.
(c)For the six months ended June 30, 2022, previously undisclosed first quarter net costs were included for comparability purposes and to display trends associated with exiting contracts during the period.
(d)For the three months ended June 30, 2022, represents costs related to the Business Combination, transaction and post-closing costs related to acquisitions, and other non-operating, non-recurring costs including $2.7 million of other non-operating, non-recurring costs, $3.1 million of reorganizational costs, and $1.2 million of acquisition-related expense.
(e)For the six months ended June 30, 2022, represents costs related to the Business Combination, transaction and post-closing costs related to acquisitions, and other non-operating, non-recurring costs including $5.9 million of other non-operating, non-recurring costs, $5.3 million of reorganizational costs, and $3.2 million of acquisition-related expense.
(f)The income tax effect of the Company’s non-GAAP reconciling items are offset by valuation allowance adjustments of the same amount given that the Company was in a full valuation allowance position for the periods presented.

EX-101.SCH 3 shcr-20220810.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 shcr-20220810_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 shcr-20220810_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Entity Emerging Growth Company Entity Emerging Growth Company Soliciting Material Soliciting Material City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Information [Line Items] Entity Information [Line Items] Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Cover [Abstract] Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Ex Transition Period Entity Ex Transition Period Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Document Period End Date Document Period End Date Class of Stock [Domain] Class of Stock [Domain] Common Stock, par value $0.0001 per share Common Class A [Member] Document Type Document Type Class of Stock [Axis] Class of Stock [Axis] Entity Registrant Name Entity Registrant Name Entity Address, City or Town Entity Address, City or Town Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $11.50 per share Redeemable Warrants [Member] Redeemable Warrants Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entities [Table] Entities [Table] Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 6 shcr-20220810_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 image.jpg GRAPHIC begin 644 image.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Aug. 10, 2022
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Aug. 10, 2022
Entity Registrant Name SHARECARE, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39535
Entity Tax Identification Number 85-1365053
Entity Address, Address Line One 255 East Paces Ferry Road NE
Entity Address, Address Line Two Suite 700
Entity Address, City or Town Atlanta
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30305
City Area Code 404
Local Phone Number 671-4000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001816233
Amendment Flag false
Common Stock, par value $0.0001 per share  
Entity Information [Line Items]  
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol SHCR
Security Exchange Name NASDAQ
Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $11.50 per share  
Entity Information [Line Items]  
Title of 12(b) Security Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $11.50 per share
Trading Symbol SHCRW
Security Exchange Name NASDAQ
XML 9 shcr-20220810_htm.xml IDEA: XBRL DOCUMENT 0001816233 2022-08-10 2022-08-10 0001816233 us-gaap:CommonClassAMember 2022-08-10 2022-08-10 0001816233 shcr:RedeemableWarrantsMember 2022-08-10 2022-08-10 0001816233 false 8-K 2022-08-10 SHARECARE, INC. DE 001-39535 85-1365053 255 East Paces Ferry Road NE Suite 700 Atlanta GA 30305 404 671-4000 false false false false Common Stock, par value $0.0001 per share SHCR NASDAQ Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $11.50 per share SHCRW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 3 24 1 false 2 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.sharecare.com/role/Cover Cover Cover 1 false false All Reports Book All Reports shcr-20220810.htm sharecareexhibit99163022.htm shcr-20220810.xsd shcr-20220810_def.xml shcr-20220810_lab.xml shcr-20220810_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "shcr-20220810.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "shcr-20220810_def.xml" ] }, "inline": { "local": [ "shcr-20220810.htm" ] }, "labelLink": { "local": [ "shcr-20220810_lab.xml" ] }, "presentationLink": { "local": [ "shcr-20220810_pre.xml" ] }, "schema": { "local": [ "shcr-20220810.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 31, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 1, "memberStandard": 1, "nsprefix": "shcr", "nsuri": "http://www.sharecare.com/20220810", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "shcr-20220810.htm", "contextRef": "i1d1b7ae73b2d438faec2a7e6c7726699_D20220810-20220810", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.sharecare.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "shcr-20220810.htm", "contextRef": "i1d1b7ae73b2d438faec2a7e6c7726699_D20220810-20220810", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "shcr_RedeemableWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable Warrants", "label": "Redeemable Warrants [Member]", "terseLabel": "Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $11.50 per share" } } }, "localname": "RedeemableWarrantsMember", "nsuri": "http://www.sharecare.com/20220810", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "terseLabel": "Common Stock, par value $0.0001 per share" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.sharecare.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 16 0001816233-22-000041-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001816233-22-000041-xbrl.zip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end